US EditionWeight Loss Drug Wegovy Use up 50% Among US Teens
- American teens increasingly used Novo Nordisk's weight-loss drug Wegovy, with a 50% rise in new prescriptions last year across the U.S.
- This growth followed Wegovy's approval for adolescents aged 12 and older in late 2022 and a January 2023 American Academy of Pediatrics recommendation to prescribe weight-loss drugs to children with obesity.
- Truveta examined electronic medical data from 1.3 million adolescents aged 12 to 17 across 30 health systems encompassing over 900 hospitals and 20,000 clinics, finding that new prescriptions for Wegovy reached 17.3 per 100,000 teens by early 2024.
- Despite losing an average 15 pounds within 6 to 12 months, the prescription rate remains a small fraction of the estimated 23,000 per 100,000 U.S. Adolescents living with obesity, amid concerns over long-term drug safety during critical development phases.
- The increased use suggests cautious acceptance but highlights limited treatment options, insurance coverage gaps, and calls for ongoing monitoring of both positive and negative medication outcomes before wider adoption.
16 Articles
16 Articles
Wegovy use up 50% among US teens - Hawaii Tribune-Herald
LOS ANGELES — American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in its use for young people with obesity, new data shared with Reuters shows. The average rate of teens beginning treatment with the highly effective Novo Nordisk drug grew 50% last year to 14.8 prescriptions per 100,000 adolescents, according to an analysis by health data firm Truveta.
Teens using weight-loss drug Wegovy jumps 50%
American teens are increasingly turning to the weight-loss drug Wegovy, as more families and their doctors gain confidence in its use for young people with obesity.This is according to new data, shared with Reuters.The average rate of teens beginning treatment with the highly effective drug grew 50% last year.This is just a fraction of the […]
Coverage Details
Bias Distribution
- 45% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
